Bleeding Disorders Treatment Includes Medicines and Transfusions of Blood, Platelets, or Clotting Factor

 

There are three general bleeding disorders treatments, such as risk reduction, medications, and replacement therapy. Bleeding disorders are a group of conditions in which there is a problem with the body's blood clotting process. Bleeding disorders such as von Willebrand disease and hemophilia result when the blood lacks certain clotting factors. Most of them are inherited, in rare cases, although, hey can develop later in life if the body makes antibodies that fight the natural clotting factors of the blood. However, the bleeding disorders treatment depends on the type and severity of the disorder.

Bleeding disorders can also be caused by side effects of certain medications, low red blood cell count, and vitamin K deficiency. Various bleeding disorders treatment options are available such as replacement therapies which include platelet transfusion, medication, clotting factor replacement, fresh frozen plasma transfusion, and iron supplementation. Patients with severe bleeding disorders may require clotting factors as a preventive measure. While individuals with moderate to severe may receive clotting factors or transfusion of blood platelets.

Factor replacement therapy is a type of treatment where clotting factors are given to replace the missing clotting factor. Moreover, bleeding disorders can cause abnormal bleeding outside and inside the body. The symptoms may vary depending on the type of disorder. Symptoms or signs may include bleeding into joints, excessive bleeding from small cuts or an injury, frequent nosebleeds, heavy menstrual bleeding, and unexplained and easy bruising. Thus, it is important to consult with a doctor to prevent complications associated with certain blood disorders.

The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. Hemophilia is a rare heredity bleeding disorder that requires treatment for life. The severity of hemophilia is determined by the amount of factor in the blood. Thus, with the increasing incidence or prevalence of bleeding disorders worldwide, the demand for bleeding disorders treatment is also increasing with a rapid pace. For example, in 2018, Bayer announced that the Japanese Ministry of Health, Labour and Welfare has approved Jivi (BAY94-9027) for the treatment of hemophilia A for adults and adolescents 12 years of age or older in Japan.